Vaccine-associated paralytic poliomyelitis in the Russian Federation in 1998-2014
| Autor: | Liubov I. Kozlovskaya, Alexandr Y. Krasota, Olga Y. Baykova, Ekaterina A. Korotkova, Anatoly P. Gmyl, Olga Ivanova, Armen K. Shakaryan, Nadezhda S. Morozova, Eremeeva Tp |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Male Pediatrics medicine.medical_specialty Time Factors Vaccination schedule medicine.disease_cause lcsh:Infectious and parasitic diseases Russia 03 medical and health sciences Paralysis medicine Humans lcsh:RC109-216 Immunization Schedule business.industry Poliovirus Incidence (epidemiology) Vaccination Infant General Medicine medicine.disease Polio Vaccination Poliomyelitis Poliovirus Vaccine Inactivated 030104 developmental biology Infectious Diseases Child Preschool Poliovirus Vaccine Oral Russian federation Female medicine.symptom business Vaccine-Associated Paralytic Poliomyelitis |
| Zdroj: | International Journal of Infectious Diseases, Vol 76, Iss, Pp 64-69 (2018) |
| ISSN: | 1878-3511 |
| Popis: | Objectives: Different polio vaccination schemes have been used in Russia: oral polio vaccine (OPV) was used in 1998–2007 and inactivated polio vaccine (IPV) followed by OPV in 2008–2014. This article presents the characteristics of vaccine-associated paralytic poliomyelitis (VAPP) cases in Russia during this period. Methods: VAPP cases were identified through the acute flaccid paralysis surveillance system, classified by the National Expert Classification Committee. Criteria for a ‘recipient VAPP’ (rVAPP) case were poliomyelitis symptoms 6–30 days after OPV administration, isolation of the vaccine virus, and residual paralysis 60 days after disease onset. Unvaccinated cases with a similar picture 6–60 days after contact with an OPV recipient were classified as ‘contact VAPP’ (cVAPP) cases. Results: During 1998–2014, 127 VAPP cases were registered: 82 rVAPP and 45 cVAPP. During the period in which only OPV was used, rVAPP cases prevailed (73.8%); cases of rVAPP were reduced during the sequential scheme period (15%). Poliovirus type 3 (39.5%) and type 2 (23.7%) were isolated more often. Vaccine-derived poliovirus types 1, 2, and 3 were isolated from three cases of cVAPP. The incidence of VAPP cases was higher during the period of OPV use (1 case/1.59 million OPV doses) than during the sequential scheme period (1 case/4.18 million doses). Conclusion: The risk of VAPP exists if OPV remains in the vaccination schedule. Keywords: Poliomyelitis, VAPP, Poliovirus vaccine, IPV, OPV |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|